Drugs / AD-104-A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05703282 | Mar 2023 → Apr 2024 | hyperlipidemia | Addpharma Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-104-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05703282 ↗ |
| Route | Oral | “PO, Single-Dose, AD-104-A” NCT05703282 ↗ |